Filter by: patients
What is Teriflunomide?

Teriflunomide is thought to prevent the interaction of cells in the immune system involved in damage to the myelin sheath. It is being used in clinical studies for relapsing/remitting Multiple Sclerosis.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 5 0
Participate in clinical trial 3 2 Efficacy_cant_tell
Other 1 0

See all 5 patients currently taking Teriflunomide

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
1
Moderate
0
Mild
1
None
0

Commonly reported side effects, conditions, and hospitalizations associated with Teriflunomide

Weight loss 1
Headaches 1
Chest pain with flushing/nausea 1

Reported Dosages

  daily 1 mg daily 7 mg daily 14 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Teriflunomide (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 2   Did not seem to work: 67%
Doctor's advice 2   Doctor's advice: 67%
Course of treatment ended 2   Course of treatment ended: 67%

See all 3 patients who’ve stopped taking Teriflunomide

Currently Taking Teriflunomide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Teriflunomide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Teriflunomide

Always
2 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Teriflunomide

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
2 100%

Cost

Paid out of pocket

Cost of Teriflunomide

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
2 100%

Report created on May 28, 2012.